Cardiovascular effects of the thiazolidinedione troglitazone
Yamada, K.; Kuzuya, H.; Nakano, T.
Nihon Rinsho. Japanese Journal of Clinical Medicine 58(2): 435-439
2000
ISSN/ISBN: 0047-1852 PMID: 10707572 Document Number: 515133
Troglitazone, a newly introduced insulin sensitizer, has been implicated in prevention and treatment of atherosclerotic cardiovascular disease especially associated with type 2 diabetes mellitus and insulin resistance. Beneficial effects of troglitazone on multiple risk factor syndrome have been reported in terms of blood pressure lowering effect and ameliorations of dyslipidemia and hyperinsulinemia. Moreover, in vitro and in vivo studies have shown vasodilating and antiatherogenic effects as well as cardioprotective action of this compound. Thus, troglitazone may have potential to prevent and delay diabetic heart disease and large vessel complications.